The acquisition includes brand names such as Carbolevure, Revitalose, Balsoclase and Toclase, representing annual sales of approximately $18 million. UCB will continue to manufacture and supply some of the transferred products during a transitional period.
UCB and Pierre Fabre have also entered into a distribution agreement under which Pierre Fabre will pursue the active marketing of UCB’s leading anti-histamine, ZyrtecSet, in the OTC market in France.
Pierre-Yves Revol, CEO of Pierre Fabre said: “The acquisition of UCB’s OTC business in these countries perfectly fits Pierre Fabre’s strategy of developing its healthcare division and enlarge its portfolio with strong brands in France, as well as in countries where the group is already well established.”